查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1806242

干细胞治疗市场按治疗类型、细胞来源、技术、给药方法、应用、治疗领域和最终用户划分－2025-2030 年全球预测

Stem Cell Therapy Market by Therapy Type, Cell Source, Technology, Mode of Administration, Application, Therapeutic Areas, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年干细胞治疗市值将达44.5亿美元，2025年成长至50.8亿美元，复合年增长率为14.33%，到2030年将达到99.5亿美元。

主要市场统计数据
基准年2024年 44.5亿美元
预计2025年 50.8亿美元
预测年份 2030 99.5亿美元
复合年增长率（%） 14.33%

创新干细胞疗法开启医疗保健新纪元，彻底改变病患治疗效果，并重新定义全球治疗模式

干细胞疗法正迅速崛起，成为现代医学中最具前景的前沿领域之一，为修復受损组织、调节免疫反应以及改善各种慢性和急性疾病患者的预后提供了前所未有的可能性。透过利用这些多功能细胞与生俱来的再生能力，研究人员和临床医生正在重新定义神经退化性疾病的治疗模式。细胞培养技术、基因编辑、生医材料和法律规范的不断进步，正在将干细胞干预从实验室的好奇心提升到切实可行的临床应用。

突破性发现和技术的融合如何推动干细胞疗法开发和应用的根本性变革

近年来，基因编辑、诱导性多功能干细胞(iPSC) 重编程以及自动化生产平台等突破性技术进步，显着改变了干细胞治疗的模式。这些进步正在汇聚，加速临床应用并扩大治疗范围。例如，基于 CRISPR 的基因编辑技术的改进使得能够精确修復患者来源细胞中的基因缺陷，为罕见遗传疾病的个人化再生干预打开了大门。

分析近期美国关税政策对干细胞治疗供应链和研究前景的广泛影响

2025年初美国新关税的出台，将对整个干细胞治疗供应链和研究生态系统产生一系列波动。关键原料、专用试剂和高精度设备的投入成本不断上涨，其中许多都来自国际采购，这给学术研究机构和商业製造商都带来了衝击。因此，采购团队正在重新谈判长期合同，并寻找具有本地製造能力的替代供应商。

透过探索不同的治疗类型、细胞来源、技术、递送方法、应用、治疗目标和最终用户来提取关键见解

透过考虑治疗类型、细胞来源、技术、给药途径、应用领域、治疗标靶和最终用户之间的相互关係，可以更清楚地洞察干细胞治疗市场。利用供体来源细胞的同种异体细胞疗法因其可扩展的生产效率而发展势头强劲，而自体细胞疗法则因其个性化的安全性而持续受到青睐，儘管其个体化处理成本更高。然而，自体干细胞疗法因其个人化的安全性而仍然具有吸引力，儘管其个体化处理成本更高。由于造血和间质平台的成熟，成体干细胞仍然是治疗的主流，而神经前驱细胞在中枢神经系统疾病的应用也正在取得进展。胚胎干细胞正在开闢一个多功能为关键的市场，而羊水和脐带细胞等周产期细胞则兼具伦理可接受性和强大的分化潜力。

绘製美洲、欧洲、中东和非洲以及亚太地区干细胞治疗市场的关键区域动态、成长机会和新兴趋势

区域动态在塑造干细胞疗法开发和商业化轨迹方面发挥着至关重要的作用。在美洲，美国凭藉其强大的资金筹措环境、完善的临床试验基础设施以及兼顾病患安全与快速治疗途径的法律规范，处于领先地位。加拿大透过对转化研究中心的策略性资助巩固了其地位，而拉丁美洲国家则开始利用经济高效的临床网络和政府支持政策来吸引国际伙伴关係。

检验全球领先开发商在不断发展的干细胞治疗产业格局中的策略定位和创新蓝图

干细胞治疗的竞争格局由在科学创新、监管环境和战略伙伴关係方面表现卓越的公司决定。主要企业已展现出透过整合专有技术和强大的生产平台，将早期研究推进到关键临床试验的能力。一些创新公司专注于基因工程同种异体细胞株係以治疗罕见遗传疾病，而另一些则致力于优化间质干细胞结构以用于治疗发炎性疾病和组织修復。

加速创新、优化营运和加强干细胞治疗合作的可行策略和最佳实践

产业领导者应优先投资模组化生产系统，以实现快速规模生产并灵活适应多种细胞类型和治疗标靶。采用一次性生物反应器和封闭式系统处理，可以帮助企业最大限度地降低交叉污染的风险，并加速各设施之间的技术转移。同时，与试剂供应商和专业设备供应商建立策略联盟，可确保优先获得关键投入，并促进合作开发倡议。

我们严格的调查方法结合了质性访谈、定量资料分析和专家检验，为干细胞治疗提供了可靠的见解。

本研究采用混合方法，整合定性和定量数据，以整体情况干细胞治疗领域。主要研究透过对领先生物製药公司的高阶主管、监管代表、学术研究人员和製造外包专业人员进行深入访谈进行。这些讨论有助于深入了解干细胞治疗的发展挑战、投资重点和应用障碍。

整合关键发现，明确未来发展路径，推动全球干细胞应用领域下一代治疗突破

技术进步、政策转变和市场动态的交汇，凸显了干细胞疗法发展的关键时刻。基因调控和细胞製造领域的突破正在克服规模化和一致性等历史性瓶颈。同时，不断发展的监管政策和策略合作正在降低发展路径的风险，并创造有利于创新的环境。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

  • 越来越多地采用干细胞衍生的外泌体疗法作为无细胞再生药物的替代品
  • 自体脂肪干细胞治疗骨关节炎疼痛的进展
  • 针对血液疾病的基因编辑干细胞疗法的监管核准途径
  • 将3D生物列印技术与诱导性多功能干细胞结合用于器官再生研究
  • 间质干细胞产品在运动医学的商业化挑战与报销策略
  • 用于脊髓损伤恢復的现成同种异体神经干细胞治疗方法的出现
  • 人工智慧在优化干细胞製造和品管工作流程的应用
  • 扩大诱导性多功能干细胞治疗神经系统疾病的临床试验
  • 利用生物材料支架进行创新干细胞疗法，以改善细胞移植和组织再生结果
  • 一种新型照护现场自体细胞治疗装置可以使治疗更易于获得且扩充性

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章 干细胞治疗市场（依治疗类型）

  • 顺势疗法
  • 自体治疗

第九章干细胞治疗市场：细胞来源

  • 成体干细胞
    • 造血干细胞
    • 间质干细胞
    • 神经干细胞
  • 胚胎干细胞
  • 诱导性多功能细胞
  • 周产期干细胞
    • 羊水干细胞
    • 脐带干细胞

第 10 章干细胞治疗市场：依技术

  • 基于生物材料的疗法
  • 体外生长
  • 基因编辑技术
  • 支架疗法

第11章 干细胞治疗市场（依给药方式）

  • 关节内
  • 肌肉注射
  • 静脉

第 12 章干细胞治疗市场：依应用

  • 药物研发
  • 再生医学
  • 组织工程

第十三章 干细胞治疗市场：依治疗领域

  • 心血管疾病
  • 血液学
  • 肌肉骨骼疾病
  • 神经系统疾病
  • 肿瘤学

第 14 章 干细胞治疗市场（依最终使用者）

  • 学术研究机构
  • 生物製药公司
  • 医院和诊所
  • 干细胞库

15.美洲干细胞治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 欧洲、中东和非洲干细胞治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

第 17 章：亚太干细胞治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十八章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • BrainStorm Cell Therapeutics Inc.
    • Merck KGaA
    • Anterogen Co., Ltd.
    • Astellas Pharma Inc.
    • Beike Biotechnology Co., Ltd.
    • Bristol-Myers Squibb Company
    • CellProthera SAS
    • Fate Therapeutics, Inc.
    • Gamida Cell Ltd.
    • Garuda Therapeutics
    • Holostem Terapie Avanzate Srl
    • Jasper Therapeutics, Inc.
    • JCR Pharmaceuticals Co., Ltd.
    • Juvena Therapeutics Inc.
    • Kangstem Biotech Co., Ltd.
    • Kite Pharma, Inc. by Gilead Sciences, Inc.
    • Lonza Group AG
    • Medeze Group
    • Mesoblast Ltd.
    • Novo Nordisk A/S
    • Plasticell
    • ReNeuron Group PLC
    • SQZ Biotechnologies Company by Stemcell Technologies
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • US Stem Cell Inc
    • Umoja Biopharma
    • Vericel Corporation

第十九章 研究人工智慧

第20章 研究统计

第21章 研究联络人

第22章 研究报导

第23章 附录

Product Code: MRR-431752EA49AD

The Stem Cell Therapy Market was valued at USD 4.45 billion in 2024 and is projected to grow to USD 5.08 billion in 2025, with a CAGR of 14.33%, reaching USD 9.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.45 billion
Estimated Year [2025] USD 5.08 billion
Forecast Year [2030] USD 9.95 billion
CAGR (%) 14.33%

Pioneering a New Era in Healthcare with Innovative Stem Cell Therapies Revolutionizing Patient Outcomes and Redefining Treatment Paradigms Globally

Stem cell therapy is rapidly emerging as one of the most promising frontiers in modern medicine, offering unprecedented potential to repair damaged tissues, modulate immune responses, and transform patient outcomes across a variety of chronic and acute conditions. By harnessing the innate regenerative capabilities of these pluripotent and multipotent cells, researchers and clinicians are redefining treatment paradigms from neurodegenerative disorders to cardiovascular disease. The convergence of advances in cell culture techniques, gene editing, biomaterials, and regulatory frameworks has elevated stem cell interventions from laboratory curiosities to viable clinical applications.

Against this backdrop, the executive summary provides a concise yet thorough exploration of the forces reshaping the stem cell therapy landscape. It examines groundbreaking technological developments, analyzes the implications of recent policy shifts, and distills critical insights drawn from segmentation and regional dynamics. Emphasis is placed on understanding how emerging cell sources and manufacturing platforms are unlocking new therapeutic avenues, while a spotlight on key stakeholders reveals strategic pathways to leadership.

Drawing on primary interviews with industry experts, secondary literature, and rigorous data validation, this overview equips decision-makers with the knowledge required to navigate complexities and capitalize on opportunities. Whether you are a researcher seeking collaboration, an investor assessing risk, or a corporate strategist charting growth, this executive summary lays the foundation for informed action and sustained innovation.

How Groundbreaking Discoveries and Technological Convergence Are Driving Fundamental Shifts in Stem Cell Therapy Development and Adoption

Recent years have witnessed transformative shifts in the stem cell therapy landscape, driven by breakthroughs in gene editing, induced pluripotent stem cell (iPSC) reprogramming, and automated manufacturing platforms. These innovations are converging to accelerate clinical translation and broaden therapeutic reach. For instance, the refinement of CRISPR-based editing techniques has enabled precise correction of genetic defects in patient-derived cells, opening doors to personalized regenerative interventions for rare inherited disorders.

Parallel advances in scaffold-based delivery systems and biomaterial engineering are enhancing cell viability and targeted engraftment, mitigating historic challenges associated with retention and survival at injury sites. Ex vivo expansion technologies further bolster scalability by allowing the production of high-quality cell populations under controlled conditions, thereby reducing variability and ensuring consistency across batches.

Moreover, public-private partnerships and cross-sector collaborations have fostered shared infrastructure, regulatory guidance, and pooled expertise. These cooperative frameworks are streamlining early-phase clinical trials, facilitating accelerated approval pathways, and de-risking investments. By strategically aligning research institutions, biopharmaceutical firms, and clinical networks, the industry is primed to transition innovative concepts into widespread adoption, marking a pivotal shift from proof-of-concept studies to robust, scalable therapeutic programs.

Analyzing the Broad Ripple Effects of Recent United States Tariff Policies on the Stem Cell Therapy Supply Chain and Research Outlook

The introduction of new tariffs by the United States in early 2025 has triggered a series of reverberations throughout the stem cell therapy supply chain and research ecosystem. Key raw materials, specialized reagents, and high-precision instrumentation-many of which are sourced internationally-have seen input costs rise, affecting both academic laboratories and commercial manufacturers. As a result, procurement teams are renegotiating long-term contracts and exploring alternative suppliers with regional manufacturing capabilities.

In addition to elevated costs, extended customs clearance times have disrupted just-in-time inventory models, compelling facilities to build buffer stocks and adapt warehouse management systems. This shift has inadvertently underscored the value of strategic localization, with some organizations electing to repatriate critical processes closer to end-markets to mitigate tariff exposure.

On the research front, regulatory bodies have shown a willingness to accommodate conditional approvals and rolling submissions in response to supply chain pressures. This flexibility has enabled certain clinical programs to maintain momentum, even as budgetary allocations are rebalanced to absorb incremental import duties. Looking ahead, stakeholders are reevaluating risk management frameworks, prioritizing vertical integration, and forging cross-border alliances to preserve operational continuity and capitalize on evolving policy landscapes.

Unlocking Critical Insights by Examining Diverse Therapy Types, Cell Sources, Technologies, Administration Modes, Applications, Therapeutic Targets, and End Users

Insight into the stem cell therapy market emerges most clearly when one considers the interplay of therapy types, cell sources, technologies, administration routes, application areas, therapeutic focus, and end-user segments. Allogeneic therapies, which leverage donor-derived cells, are gaining momentum thanks to scalable manufacturing efficiencies, whereas autologous approaches continue to appeal for their personalized safety profile despite higher individualized processing costs. From a sourcing perspective, adult stem cells remain a mainstay thanks to established hematopoietic and mesenchymal platforms, while neural precursors are advancing for central nervous system indications. Embryonic stem cells are carving niches where pluripotency is essential, complemented by perinatal populations such as amniotic fluid and umbilical cord cells that combine ethical acceptability with robust differentiation capacity.

On the technological front, biomaterial-enhanced constructs and scaffold systems are optimizing cell delivery and retention. Gene-edited technologies are refining therapeutic specificity by eliminating immunogenic markers and correcting pathogenic variants. Ex vivo expansion solutions are seamlessly integrated with automated bioreactors to deliver consistent cell quality at scale. In parallel, the choice of administration route-ranging from intra-articular injections for musculoskeletal applications to intravenous infusions for systemic disorders-is being tailored to both clinical objectives and patient comfort.

Applications in drug discovery are utilizing stem cell-derived models to predict toxicity and efficacy, while regenerative medicine platforms target tissue restoration across cardiovascular, neurological, and musculoskeletal domains. Tissue engineering collaborations are producing hybrid constructs for organ repair. Across these domains, academic and research institutes fuel basic science discoveries, biopharmaceutical companies shepherd translational programs, hospitals and clinics drive clinical trial enrollment and real-world evidence collection, and specialized stem cell banks underpin both supply reliability and quality assurance.

Mapping Key Regional Dynamics, Growth Opportunities, and Emerging Trends Across the Americas, Europe Middle East Africa, and Asia-Pacific Stem Cell Therapy Markets

Regional dynamics play a decisive role in shaping the trajectory of stem cell therapy development and commercialization. In the Americas, the United States leads with a robust funding environment, established clinical trial infrastructure, and a regulatory framework that balances patient safety with accelerated pathways. Canada is bolstering its position through strategic funding of translational research hubs, while Latin American countries are beginning to attract international partnerships by leveraging cost-effective clinical networks and supportive government incentives.

Within Europe, Middle East, and Africa, Europe's landscape is characterized by harmonized regulatory guidelines and a vibrant community of centers of excellence. Western European nations are driving first-in-human studies, while emerging markets in the Middle East and North Africa are investing in biomanufacturing capacity and public-private innovation clusters. Collaborative frameworks between the European Medicines Agency and regional authorities are laying the foundation for unified compassionate use programs and standardized quality controls.

In the Asia-Pacific arena, nations such as Japan and South Korea have established favorable cell therapy roadmaps, including conditional approvals and reimbursement models that mitigate development risk. China's expansive clinical trial footprint and growing network of contract development and manufacturing organizations present both opportunities and competitive pressures. India, Australia, and Southeast Asian nations are accelerating research through government grants and cross-border research partnerships, creating a diverse ecosystem that spans early-stage discovery to late-stage commercialization.

Examining Strategic Positioning and Innovation Roadmaps of Leading Global Developers in the Evolving Stem Cell Therapy Industry Landscape

The competitive landscape of stem cell therapy is defined by organizations that excel in scientific innovation, regulatory navigation, and strategic partnerships. Leading companies have demonstrated the capacity to advance early-stage research into pivotal trials by integrating proprietary technologies with robust manufacturing platforms. Some innovators are focusing on gene-edited allogeneic cell lines to address rare genetic disorders, while others are optimizing mesenchymal stem cell constructs for inflammatory conditions and tissue repair.

Strategic alliances between biotech firms and large pharmaceutical companies are accelerating late-stage clinical development, leveraging established distribution channels and deep reimbursement expertise. Contract development and manufacturing organizations are stepping into the spotlight by offering end-to-end solutions, from cell banking through fill-and-finish operations, thereby de-risking capital expenditure for small to mid-sized developers.

In parallel, a number of academic spin-off enterprises are carving out niches by translating novel differentiation protocols or biomaterial formulations into early-phase trials. Venture capital and strategic corporate investors continue to back these high-potential ventures, focusing on pipelines that span oncology to neurological diseases. Collectively, these stakeholders are reshaping the sector by aligning scientific ambition with commercial pragmatism, setting new benchmarks for efficacy, safety, and scalability.

Implementable Strategies and Best Practices Designed to Accelerate Innovation, Optimize Operational Frameworks, and Enhance Collaboration in Stem Cell Therapy

Industry leaders should prioritize investment in modular manufacturing systems that allow rapid scale-up and flexible adaptation to multiple cell types and therapeutic targets. By adopting single-use bioreactors and closed-system processing, organizations can minimize cross-contamination risk and accelerate technology transfer across facilities. Concurrently, forging strategic alliances with reagent suppliers and specialized equipment vendors will secure preferential access to critical inputs and foster co-development initiatives.

To navigate evolving regulatory landscapes, companies must implement proactive engagement strategies with health authorities, submitting data packages that emphasize process validation and real-world evidence. Leveraging adaptive trial designs can shorten timelines while preserving rigorous safety and efficacy standards. Building global trial networks and harmonizing clinical protocols will also reduce duplicate efforts and streamline patient recruitment.

Furthermore, embracing digital health solutions-such as remote monitoring, electronic patient-reported outcomes, and blockchain-enabled supply chain tracking-will enhance transparency, patient adherence, and quality control. Finally, cultivating cross-disciplinary talent through targeted training programs and academic collaborations will ensure the workforce remains adept at integrating emerging science with commercial imperatives, laying the groundwork for sustainable growth.

Rigorous Methodological Approach Combining Qualitative Interviews, Quantitative Data Analysis, and Expert Validation to Ensure Robust Stem Cell Therapy Insights

This research is founded upon a mixed-methods approach that integrates qualitative and quantitative data to produce a holistic view of the stem cell therapy sector. Primary research was conducted through in-depth interviews with executives from leading biopharmaceutical firms, regulatory agency representatives, academic investigators, and contract manufacturing experts. These discussions provided nuanced understanding of development challenges, investment priorities, and adoption barriers.

Secondary research encompassed a thorough review of peer-reviewed publications, patent filings, government policy documents, and public company disclosures. Data points were triangulated to verify consistency and identify divergent trends across sources. Proprietary databases tracking clinical trial activities, technology licensing agreements, and capital investment flows were also leveraged to ensure comprehensive coverage.

All quantitative inputs underwent rigorous validation through cross-referencing with expert feedback. Key assumptions were stress-tested under multiple scenarios to assess impact on operational and regulatory variables. The resulting framework ensures that insights are both robust and actionable, offering stakeholders a reliable foundation for strategic decision-making in this rapidly evolving domain.

Synthesizing Critical Discoveries and Identifying Future Pathways to Propel the Next Generation of Therapeutic Breakthroughs in Stem Cell Applications Worldwide

The synthesis of technological advances, policy shifts, and market dynamics underscores a pivotal moment for the maturation of stem cell therapies. Breakthroughs in gene regulation and cell manufacturing are converging to overcome historical bottlenecks in scale and consistency. At the same time, evolving regulatory policies and strategic collaborations are de-risking development pathways and fostering an environment conducive to innovation.

Segmentation insights reveal that no single approach will dominate; rather, a diversified portfolio encompassing allogeneic and autologous products, multiple cell sources, and varied delivery platforms will characterize the next phase of growth. Regional analyses highlight that global market penetration will depend on tailoring strategies to local regulatory, reimbursement, and infrastructure conditions.

Ultimately, success in this arena will hinge on aligning scientific rigor with commercial agility, forging partnerships across the ecosystem, and maintaining an unwavering focus on patient-centered outcomes. By synthesizing these critical discoveries and identifying future pathways, stakeholders are better positioned to usher in the next generation of therapeutic breakthroughs and deliver transformative care to patients around the world.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising adoption of exosome-based therapeutics derived from stem cells as cell-free regenerative medicine alternatives
  • 5.2. Advancements in autologous adipose-derived stem cell therapies for osteoarthritis pain management
  • 5.3. Regulatory approval pathways for gene-edited stem cell therapies targeting hematologic disorders
  • 5.4. Integration of 3D bioprinting techniques with induced pluripotent stem cells for organ regeneration research
  • 5.5. Commercialization challenges and reimbursement strategies for mesenchymal stem cell products in sports medicine
  • 5.6. Emergence of off-the-shelf allogeneic neural stem cell treatments for spinal cord injury recovery
  • 5.7. Application of artificial intelligence in optimizing stem cell manufacturing and quality control workflows
  • 5.8. Clinical trial expansions targeting neurological disorders with induced pluripotent stem cell therapies
  • 5.9. Innovations in biomaterial scaffolds improving cell engraftment and tissue regeneration outcomes in stem cell therapy
  • 5.10. Emerging point-of-care autologous cell therapy devices enhancing treatment accessibility and scalability

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Stem Cell Therapy Market, by Therapy Type

  • 8.1. Introduction
  • 8.2. Allogeneic Therapy
  • 8.3. Autologous Therapy

9. Stem Cell Therapy Market, by Cell Source

  • 9.1. Introduction
  • 9.2. Adult Stem Cells
    • 9.2.1. Hematopoietic Stem Cells
    • 9.2.2. Mesenchymal Stem Cells
    • 9.2.3. Neural Stem Cells
  • 9.3. Embryonic Stem Cells
  • 9.4. Induced Pluripotent Stem Cells
  • 9.5. Perinatal Stem Cells
    • 9.5.1. Amniotic Fluid Stem Cells
    • 9.5.2. Umbilical Cord Stem Cells

10. Stem Cell Therapy Market, by Technology

  • 10.1. Introduction
  • 10.2. Biomaterial Based Therapy
  • 10.3. Ex Vivo Expansion
  • 10.4. Gene Edited Technologies
  • 10.5. Scaffold Based Therapy

11. Stem Cell Therapy Market, by Mode of Administration

  • 11.1. Introduction
  • 11.2. Intra-articular
  • 11.3. Intramuscular
  • 11.4. Intravenous

12. Stem Cell Therapy Market, by Application

  • 12.1. Introduction
  • 12.2. Drug Discovery & Development
  • 12.3. Regenerative Medicine
  • 12.4. Tissue Engineering

13. Stem Cell Therapy Market, by Therapeutic Areas

  • 13.1. Introduction
  • 13.2. Cardiovascular Diseases
  • 13.3. Hematology
  • 13.4. Musculoskeletal Disorders
  • 13.5. Neurological Disorders
  • 13.6. Oncology

14. Stem Cell Therapy Market, by End User

  • 14.1. Introduction
  • 14.2. Academic & Research Institutes
  • 14.3. Biopharmaceutical Companies
  • 14.4. Hospitals & Clinics
  • 14.5. Stem Cell Banks

15. Americas Stem Cell Therapy Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Stem Cell Therapy Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Stem Cell Therapy Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. BrainStorm Cell Therapeutics Inc.
    • 18.3.2. Merck KGaA
    • 18.3.3. Anterogen Co., Ltd.
    • 18.3.4. Astellas Pharma Inc.
    • 18.3.5. Beike Biotechnology Co., Ltd.
    • 18.3.6. Bristol-Myers Squibb Company
    • 18.3.7. CellProthera SAS
    • 18.3.8. Fate Therapeutics, Inc.
    • 18.3.9. Gamida Cell Ltd.
    • 18.3.10. Garuda Therapeutics
    • 18.3.11. Holostem Terapie Avanzate S.r.l.
    • 18.3.12. Jasper Therapeutics, Inc.
    • 18.3.13. JCR Pharmaceuticals Co., Ltd.
    • 18.3.14. Juvena Therapeutics Inc.
    • 18.3.15. Kangstem Biotech Co., Ltd.
    • 18.3.16. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 18.3.17. Lonza Group AG
    • 18.3.18. Medeze Group
    • 18.3.19. Mesoblast Ltd.
    • 18.3.20. Novo Nordisk A/S
    • 18.3.21. Plasticell
    • 18.3.22. ReNeuron Group PLC
    • 18.3.23. SQZ Biotechnologies Company by Stemcell Technologies
    • 18.3.24. Takara Bio Inc.
    • 18.3.25. Thermo Fisher Scientific Inc.
    • 18.3.26. U.S. Stem Cell Inc
    • 18.3.27. Umoja Biopharma
    • 18.3.28. Vericel Corporation

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. STEM CELL THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. STEM CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. STEM CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. STEM CELL THERAPY MARKET: RESEARCHAI
  • FIGURE 30. STEM CELL THERAPY MARKET: RESEARCHSTATISTICS
  • FIGURE 31. STEM CELL THERAPY MARKET: RESEARCHCONTACTS
  • FIGURE 32. STEM CELL THERAPY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. STEM CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STEM CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELL THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ALLOGENEIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AUTOLOGOUS THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEURAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EMBRYONIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELL THERAPY MARKET SIZE, BY AMNIOTIC FLUID STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELL THERAPY MARKET SIZE, BY UMBILICAL CORD STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOMATERIAL BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELL THERAPY MARKET SIZE, BY EX VIVO EXPANSION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GENE EDITED TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELL THERAPY MARKET SIZE, BY SCAFFOLD BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRA-ARTICULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELL THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELL THERAPY MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELL THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELL THERAPY MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELL THERAPY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELL THERAPY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELL THERAPY MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELL THERAPY MARKET SIZE, BY STEM CELL BANKS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 113. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 114. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 115. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES STEM CELL THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. CANADA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 131. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 132. CANADA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 133. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 134. CANADA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 135. CANADA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. CANADA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. CANADA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 138. CANADA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 139. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. CANADA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 142. CANADA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 145. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 148. MEXICO STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 149. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 150. MEXICO STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 151. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 152. MEXICO STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 153. MEXICO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. MEXICO STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 155. MEXICO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. MEXICO STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 157. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. MEXICO STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 159. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 160. MEXICO STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 161. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. MEXICO STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 166. BRAZIL STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 167. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 168. BRAZIL STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 169. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 170. BRAZIL STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 171. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. BRAZIL STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 173. BRAZIL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 174. BRAZIL STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 175. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. BRAZIL STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 178. BRAZIL STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 179. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. BRAZIL STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 181. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 184. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 185. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 186. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 187. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 188. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 189. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 193. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 195. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 196. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 197. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. ARGENTINA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED KINGDOM STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 240. GERMANY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 241. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 242. GERMANY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 243. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 244. GERMANY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 245. GERMANY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. GERMANY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. GERMANY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. GERMANY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 249. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. GERMANY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 251. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 252. GERMANY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 253. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 255. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 258. FRANCE STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 259. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 260. FRANCE STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 261. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 263. FRANCE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 265. FRANCE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 267. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 270. FRANCE STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 271. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. FRANCE STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 273. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 275. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 277. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 278. RUSSIA STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 279. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 280. RUSSIA STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 281. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. RUSSIA STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. RUSSIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. RUSSIA STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 285. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. RUSSIA STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 287. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 288. RUSSIA STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 289. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. RUSSIA STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 291. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 294. ITALY STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 295. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 296. ITALY STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 297. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 298. ITALY STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 299. ITALY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. ITALY STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. ITALY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. ITALY STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 303. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ITALY STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 305. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 306. ITALY STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 307. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 309. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 312. SPAIN STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 313. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 314. SPAIN STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 315. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 317. SPAIN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 319. SPAIN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 321. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN STEM CELL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 323. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN STEM CELL THERAPY MARKET SIZE, BY THERAPEUTIC AREAS, 2025-2030 (USD MILLION)
  • TABLE 325. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN STEM CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 331. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY ADULT STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 333. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY PERINATAL STEM CELLS, 2025-2030 (USD MILLION)
  • TABLE 335. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 337. UNITED ARAB EMIRATES STEM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED ARAB EMI